Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis.
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Central Nervous System Herpes Simplex and Varicella-Zoster Virus Infections in Natalizumab-Treated Patients.
Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab For Relapsing-Remitting Multiple Sclerosis.
Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
Corticosteroids for treating optic neuritis.
Mechanism for p38α-mediated experimental autoimmune encephalomyelitis.
Age-dependent effects on the treatment response of natalizumab in MS patients.
MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis.
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial.
An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.
Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation.
Multiple sclerosis: Spinal cord grey matter loss correlates with disability in MS.
1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis.
Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.
Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program.
CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON)
Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis.
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Sexual dysfunction ın multiple sclerosis: Gender differences.
Lessons from Jack Griffin and the "pathogenesis of peripheral nerve disease".

Pages